- Home
- FENC vs ALDX Comparison
FENC vs ALDX Comparison
Compare FENC & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- ALDX
- Stock Information
- Founded
- FENC 1996
- ALDX 2004
- Country
- FENC United States
- ALDX United States
- Employees
- FENC N/A
- ALDX N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- ALDX Health Care
- Exchange
- FENC Nasdaq
- ALDX Nasdaq
- Market Cap
- FENC 156.9M
- ALDX 133.7M
- IPO Year
- FENC 2001
- ALDX 2014
- Fundamental
- Price
- FENC $7.94
- ALDX $2.13
- Analyst Decision
- FENC Strong Buy
- ALDX Strong Buy
- Analyst Count
- FENC 2
- ALDX 2
- Target Price
- FENC $13.00
- ALDX $9.50
- AVG Volume (30 Days)
- FENC 105.2K
- ALDX 1.2M
- Earning Date
- FENC 05-13-2025
- ALDX 05-14-2025
- Dividend Yield
- FENC N/A
- ALDX N/A
- EPS Growth
- FENC N/A
- ALDX N/A
- EPS
- FENC N/A
- ALDX N/A
- Revenue
- FENC $30,912,000.00
- ALDX N/A
- Revenue This Year
- FENC N/A
- ALDX N/A
- Revenue Next Year
- FENC $58.65
- ALDX N/A
- P/E Ratio
- FENC N/A
- ALDX N/A
- Revenue Growth
- FENC N/A
- ALDX N/A
- 52 Week Low
- FENC $3.96
- ALDX $1.14
- 52 Week High
- FENC $8.56
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- FENC 66.93
- ALDX 38.93
- Support Level
- FENC $7.79
- ALDX $2.10
- Resistance Level
- FENC $8.34
- ALDX $2.30
- Average True Range (ATR)
- FENC 0.46
- ALDX 0.15
- MACD
- FENC 0.06
- ALDX 0.06
- Stochastic Oscillator
- FENC 76.75
- ALDX 37.93
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.